Objective: In this study, the effects of enteral nutrition nursing care intervention under overall nutrition management on nutritional condition and life quality of NSCLC patients treated by Apatinib combined with chemoradiotherapy were discussed and analyzed. Methods: Totally 86 inoperable stage-III NSCLC patients hospitalized from April 2018 to January 2020 were recruited and divided into two groups, the control group and the observation group (n=43 for each group), based on the date of admission. The two groups of patients both received Apatinib combined with chemoradiotherapy. Based on chemoradiotherapy, the control group received routine enteral nutrition intervention while the observation group received enteral nutrition nursing care intervention under overall nutrition management. The nutritional indices, changes in nutritional knowledge level, changes in T-lymphocyte subsets and incidences of adverse reactions to chemotherapy in each group of patients were compared before and after intervention. Results: After intervention, the patients in the observation group had remarkably higher nutritional indices (P<0.05), as well as higher nutritional knowledge level than those of the control group. In addition, the percentages of CD3+, CD4+: cells, values of CD4+/CD8+, and SF-36 scores in the observation group were significantly higher than those in the control group (P<0.05); while the incidence of grade III IV adverse reactions in the observation group was significantly lower than that in the control group (13.95% vs. 32.56%, P<0.05). Conclusion: For those patients with inoperable stage III NSCLC treated by Apatinib combined with chemoradiotherapy, nursing intervention of enteral nutrition under full nutrition management overall can effectively improve their nutritional condition and knowledge level, enhance their life quality, protect their immune function, and reduce the incidence of serious adverse reactions to chemoradiotherapy. Therefore, this method is worthy of clinical promotion.

OBJECTIVE This study was to explore the expression of human cervical cancer oncogene-1 (HCCR-1) in colon cancer and its clinical significance. METHODS RT-PCR, immunohistochemistry and Western blot assay were employed to detect HCCR-1 expression in 152 colon cancers, 43 adjacent non-cancerous tissues and 37 normal tissues. In addition, immunohistochemistry was done to detect CEA in colon cancers. RESULTS The mRNA expression of HCCR-1 in colon cancers was higher than that in the adjacent non-cancerous tissues (P < 0.05), and the mRNA expression of HCCR-1 in adjacent non-cancerous tissues was higher than that in normal tissues (P < 0.05). The positive rate of HCCR-1 in colon cancers was 80.9%, which was higher than that in adjacent non-cancerous tissues (P < 0.05). Almost no HCCR-1 expression was observed in normal tissues, weak expression in adjacent non-cancerous tissues and strong expression in colon cancers. The positive rate of HCCR-1 in colon cancer at Duke stage B-C was 87.3%, which was higher than that in stage A colon cancer (63.6%, P < 0.05). CONCLUSION HCCR-1 is over-expressed in colon cancers, indicating that HCCR-1 may participate in occurrence and development of colon cancer and has a correlation with the pathological progress of colon cancer progression.